药明生物在上海开建15万平方米全球创新生物药研发制药一体化中心
药明生物在上海开建15万平方米全球创新生物药研发制药一体化中心
(*Please scroll down for English news.)
中国上海，2018年11月22日
全球领先的开放式生物制药技术平台公司药明生物（WuXi Biologics, 2269.HK）今日宣布在上海奉贤正式开建全球创新生物药研发制药一体化中心。
中共上海市奉贤区委副书记、区长华源先生（左五），上海市科委党委秘书长谢文澜先生（右四），上海市经信委副巡视员史文军先生（左三），上海市奉贤区人民政府副区长顾佾先生（右三），东方美谷董事长朱德才先生（右一），上海市发改委高技术产业处副处长刘永千先生（左一），上海市商务委国际贸易处正处级副处长阎蓓女士（左二），药明康德集团董事长李革博士（右五），药明生物首席执行官陈智胜博士（左四），药明康德常务副总裁刘晓钟先生（右二）
药明生物全球创新生物药研发制药一体化中心效果图
药明生物全球创新生物药研发制药一体化中心规划建筑面积达15万平方米，其设计及建设将符合cGMP国际先进标准，并充分运用模块化和灵活化理念，有机整合生物药发现、开发、临床和商业化生产等研发环节于一体。建成后，该中心将成为全球最大的生物药研发制药中心之一，可容纳3000多位科学家工作。
药明生物首席执行官陈智胜博士表示：“今天我们很高兴见证药明生物全球创新生物药研发制药一体化中心正式奠基，这将助力公司进一步拓宽赋能平台，通过健全强大的全球供应链网络为合作伙伴提供符合全球质量标准的生物药，降低开发和生产成本，最终造福全球病患。”
关于药明生物
药明生物（股票代码：2269.HK）作为一家香港上市公司，是全球领先的开放式、一体化生物制药能力和技术赋能平台。公司为全球生物制药公司和生物技术公司提供全方位的端到端研发服务，帮助任何人、任何公司发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。截至2018年6月30日，在药明生物平台上研发的综合项目达187个，包括98个处于临床前研究阶段，78个在临床早期（I期，II期）阶段，10个在后期临床（III期）以及1个在商业化生产阶段。预计到2021年，公司在中国、爱尔兰、新加坡、美国规划的生物制药生产基地合计产能约22万升，这将有力确保公司通过健全强大的全球供应链网络为客户提供符合全球质量标准的生物药。如需更多信息，请访问：www.wuxibiologics.com.cn。
WuXi Biologics Commenced Construction of 1.6 million sq. ft. Biologics Innovation Center in Shanghai
SHANGHAI, November 22, 2018
WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that construction of a global innovation center has commenced in the district of Fengxian in Shanghai.
The new state-of-the-art biologics center will integrate biologics discovery, development, clinical and commercial manufacturing which will be built to meet global cGMP standards while implementing modular and flexible design. This will be one of the largest facilities of its kind with 1.6 million sq. ft. and will accommodate more than 3000 scientists.
“The commencement of this new biologics center will further expand WuXi Biologics’ unparalleled capacities and we are glad to witness its construction today. WuXi Biologics is committed to developing and manufacturing biologics more cost effectively as well as to providing a robust supply chain network for our global partners to benefit patients worldwide,” said Dr. Chris Chen, Chief Executive Officer of WuXi Biologics.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. As of June 30, 2018, there were a total of 187 integrated projects, including 98 projects in pre-clinical development stage, 78 projects in early-phase (phase I and II) clinical development, 10 projects in late-phase (phase III) development and 1 project in commercial manufacturing. With total estimated capacity of biopharmaceutical production planned in China, Ireland, Singapore and US reaching 220,000 liters by 2021, we will provide our biomanufacturing partners with a robust and premier-quality global supply chain network. For more information on WuXi Biologics, please visit www.wuxibiologics.com.
注：本信息不构成药明生物的信息披露或投资建议